$PRLD
Prelude Therapeutics Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020052747 Filed on November 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.850M $1.390M
YoY Change 105.04%
% of Gross Profit
Research & Development $15.29M $5.490M
YoY Change 178.56%
% of Gross Profit
Depreciation & Amortization $140.0K $90.00K $160.0K
YoY Change 55.56%
% of Gross Profit
Operating Expenses $18.14M $6.884M
YoY Change 163.57%
Operating Profit -$18.14M -$6.884M
YoY Change 163.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.384M $150.0K
YoY Change 822.67%
Pretax Income -$16.76M -$6.730M
YoY Change 149.03%
Income Tax
% Of Pretax Income
Net Earnings -$16.76M -$6.730M -$5.556M
YoY Change 149.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.254M -$1.58
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.8M
YoY Change
Cash & Equivalents $234.8M $27.64M
Short-Term Investments
Other Short-Term Assets $3.300M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $238.1M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.600M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.581M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $238.1M
Total Long-Term Assets $1.581M
Total Assets $239.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.074M
YoY Change
Accrued Expenses $6.285M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $11.36M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $15.00K
YoY Change
Total Long-Term Liabilities $15.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.36M
Total Long-Term Liabilities $15.00K
Total Liabilities $11.37M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$88.18M
YoY Change
Common Stock $316.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $228.3M -$39.70M -$33.26M
YoY Change
Total Liabilities & Shareholders Equity $239.7M
YoY Change

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$16.76M -$6.730M -$5.556M
YoY Change 149.03%
Depreciation, Depletion And Amortization $140.0K $90.00K $160.0K
YoY Change 55.56%
Cash From Operating Activities -$12.51M -$5.630M -$11.57M
YoY Change 122.2%
INVESTING ACTIVITIES
Capital Expenditures -$170.0K $440.0K -$140.0K
YoY Change -138.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$170.0K -$440.0K -$140.0K
YoY Change -61.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 217.8M -30.00K 29.85M
YoY Change -725966.67%
NET CHANGE
Cash From Operating Activities -12.51M -5.630M -11.57M
Cash From Investing Activities -170.0K -440.0K -140.0K
Cash From Financing Activities 217.8M -30.00K 29.85M
Net Change In Cash 205.1M -6.100M 18.14M
YoY Change -3461.97%
FREE CASH FLOW
Cash From Operating Activities -$12.51M -$5.630M -$11.57M
Capital Expenditures -$170.0K $440.0K -$140.0K
Free Cash Flow -$12.34M -$6.070M -$11.43M
YoY Change 103.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Assets
Assets
239681000
CY2019Q4 us-gaap Assets
Assets
21871000
CY2019Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
258000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5074000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6285000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11359000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4835000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000
CY2020Q3 us-gaap Liabilities
Liabilities
11374000
CY2019Q4 us-gaap Liabilities
Liabilities
4840000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
66443000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.38
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
228307000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88176000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2584000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
18144000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6884000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316479000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5712000
CY2020Q3 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
2538000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239681000
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15293000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5490000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33605000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15430000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2851000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1394000
us-gaap Operating Expenses
OperatingExpenses
39317000
us-gaap Operating Expenses
OperatingExpenses
18014000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18144000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6884000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18014000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1384000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1638000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
483000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16760000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.25
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.83
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.80
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3194471
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1713371
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2380100
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1622546
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
362000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9511000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58561000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
627000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11408000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-69311000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
146211000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
166630000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1472000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-22693000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
82000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5241000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-27852000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
141000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5556000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-33262000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
297000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-39699000
us-gaap Profit Loss
ProfitLoss
-37679000
us-gaap Profit Loss
ProfitLoss
-17531000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
409000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
254000
us-gaap Share Based Compensation
ShareBasedCompensation
2461000
us-gaap Share Based Compensation
ShareBasedCompensation
520000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1924000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
344000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1931000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-76000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3472000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-19000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31330000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17196000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
292000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
581000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-292000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-581000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167929000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
258000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
31000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
96000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
247535000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29822000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
215913000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12045000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18879000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15595000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
234792000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27640000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
90000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
108000
prld Offering Costs In Accrued Expenses And Other Current Liabilities
OfferingCostsInAccruedExpensesAndOtherCurrentLiabilities
220000
prld Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
1079000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. Prior to the IPO, significant areas that required management&#8217;s estimates included the fair value of the Company&#8217;s common stock, stock-based compensation assumptions and accrued clinical trial expenses. Subsequent to the IPO, the most significant estimate relates to accrued clinical trial expenses.</p>
CY2020Q3 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
3763000
CY2019Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
658000
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.8646
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7961906
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22948354
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2099000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1631000
CY2020Q3 prld Accrued Offering Costs Current
AccruedOfferingCostsCurrent
220000
CY2020Q3 prld Accrued Professional Services And Other Liabilities Current
AccruedProfessionalServicesAndOtherLiabilitiesCurrent
203000
CY2019Q4 prld Accrued Professional Services And Other Liabilities Current
AccruedProfessionalServicesAndOtherLiabilitiesCurrent
314000
prld Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1472000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
297000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2461000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
520000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2269742
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4594130
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
98254
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.98
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115736
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6649882
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
783236
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.64
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153700000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22300000
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6649882
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
783236

Files In Submission

Name View Source Status
0001564590-20-052747-index-headers.html Edgar Link pending
0001564590-20-052747-index.html Edgar Link pending
0001564590-20-052747.txt Edgar Link pending
0001564590-20-052747-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
prld-10q_20200930.htm Edgar Link pending
prld-20200930.xml Edgar Link completed
prld-20200930.xsd Edgar Link pending
prld-20200930_cal.xml Edgar Link unprocessable
prld-20200930_def.xml Edgar Link unprocessable
prld-20200930_lab.xml Edgar Link unprocessable
prld-20200930_pre.xml Edgar Link unprocessable
prld-ex311_9.htm Edgar Link pending
prld-ex312_8.htm Edgar Link pending
prld-ex31_234.htm Edgar Link pending
prld-ex321_7.htm Edgar Link pending
prld-ex322_6.htm Edgar Link pending
prld-ex32_235.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending